CorMedix Inc. (NASDAQ:CRMD – Get Free Report) CEO Joseph Todisco bought 10,000 shares of the business’s stock in a transaction on Friday, September 8th. The stock was acquired at an average cost of $3.71 per share, for a total transaction of $37,100.00. Following the acquisition, the chief executive officer now directly owns 219,726 shares of the company’s stock, valued at $815,183.46. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
CorMedix Trading Down 1.3 %
CRMD opened at $3.70 on Monday. The business’s 50 day moving average is $4.04 and its 200-day moving average is $4.41. The stock has a market cap of $202.78 million, a PE ratio of -4.30 and a beta of 1.85. CorMedix Inc. has a twelve month low of $2.71 and a twelve month high of $6.09.
CorMedix (NASDAQ:CRMD – Get Free Report) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). CorMedix had a negative net margin of 45,003.03% and a negative return on equity of 68.87%. As a group, analysts forecast that CorMedix Inc. will post -0.91 EPS for the current year.
Institutional Investors Weigh In On CorMedix
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on CRMD. Needham & Company LLC cut their target price on shares of CorMedix from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Royal Bank of Canada started coverage on CorMedix in a research note on Thursday, August 10th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, JMP Securities raised their target price on CorMedix from $16.00 to $19.00 in a research note on Friday, May 19th.
CorMedix Company Profile
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.
- Five stocks we like better than CorMedix
- How to Calculate Return on Investment (ROI)
- MarketBeat Week in Review – 9/4 – 9/8
- How to Use the MarketBeat Stock Split Calculator
- The Best 5 Small Cap AI Companies to Buy Now
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.